INVAInnoviva, Inc.
$21.21+11% 1Y
$21.21
$16.6752 weeks$24.24
The financials
Innoviva, Inc. by the numbers
Innoviva, Inc. (INVA) reported revenue of $120M in Q2 2026 (quarter ended Jun 30, 2026), up 19% from the same quarter a year earlier. That came with a gross margin of 76% and net loss of $83M. For the full year FY2025, revenue was $411M (+15% year on year) and net income $271M. Its largest product in Q2 2026 was Royalty at $56M, 46% of the disclosed total, well ahead of Xacduro at 18%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $120M | $100M | +19% |
| Gross profit | $91M | $83M | +9.0% |
| Operating income | $51M | $49M | +4.3% |
| Net income | −$83M | $64M | to a loss |
| Diluted EPS | −$1.14 | $0.77 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $56M | 46% |
| Xacduro | $22M | 18% |
| Giapreza | $22M | 18% |
| License And Other | $11M | 9.5% |
| Xerava | $6.7M | 5.6% |
| Cost Reimbursement | $1.8M | 1.5% |
| ZEVTERA | $351K | 0.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $121.4M (+24%)
License And Other grew +1162% year on yearRoyalty -12% year on year
Segment Latestquarter on quarteryear on year
- Royalty$56.3M$56.3Mquarter on quarter +2.1%year on year -12%+2.1%-12%
- Xacduro$22.4M$22.4Mquarter on quarter +24%year on year +109%+24%+109%
- Giapreza$22.3M$22.3Mquarter on quarter +10%year on year +29%+10%+29%
- License And Other$11.5M$11.5Mquarter on quarter +689%year on year +1162%+689%+1162%
- Xerava$6.7M$6.7Mquarter on quarter +156%year on year -5.0%+156%-5.0%
- Cost Reimbursement$1.8M$1.8Mquarter on quarter n/ayear on year +125%n/a+125%
- ZEVTERA$351.0K$351.0Kquarter on quarter -20%year on year +3.5%-20%+3.5%